dtx
The research targets people with complex regional pain syndrome, post-stroke pain, and other pain-induced conditions.
It will focus on creating digital solutions for ophthalmic, neurological and psychiatric disorders.
They will develop and commercialise three novel digital therapeutic products.
The app provides personalised treatment guidance to users based on their BP record, habit logs and behavioural changes.
The new tool must be prescribed by a doctor, but is not intended to replace medications.
The deal is expected to close this summer, subject to stockholder approval, and will raise $113 million for the combined company.
Former CEO Ed Cox tells the story of Dthera Sciences and outlines how the digital therapeutics landscape has shifted since his company's heyday.
The investment from "a leading national Integrated Delivery Network" brings the Series D's total to $100 million.
Industry regulatory leaders outline the best approaches for digital health companies looking to make sense of FDA's long-in-the-tooth enforcement discretion guidelines.
The randomized controlled trial of the jointly-developed digital therapeutics will be conducted using Verily's Project Baseline and enroll up to 540 patients.